Literature DB >> 19080756

Update on medication-induced peripheral neuropathy.

Louis H Weimer1, Noor Sachdev.   

Abstract

Despite improvements in the identification of causes of peripheral neuropathy, idiopathic polyneuropathy remains common. Medication and toxic neuropathy account for a small but important percentage of potentially preventable or reversible causes of neuropathy. New drugs that can induce neuropathy have been approved over the past several years, including the anticancer agents bortezomib, ixabepilone, and oxaliplatin. We review the neurotoxic effects of tumor necrosis factor-alpha blockers infliximab and etanercept, the inflammatory arthritis agent leflunomide, and the antibiotic linezolid. The controversy of statin-induced neuropathy continues to unfold; the large Fremantle Diabetes Study has suggested that statins may have neuroprotective effects. Dichloroacetate is a promising agent for lactic acidosis-associated disorders, but toxic neuropathy is a treatment-limiting factor. We also describe a progressive inflammatory neuropathy in swine slaughterhouse workers that appears to be a toxin-induced immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19080756     DOI: 10.1007/s11910-009-0011-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  63 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

2.  Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy.

Authors:  Oliver C Singer; Bettina Otto; Helmuth Steinmetz; Ulf Ziemann
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

3.  Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide.

Authors:  C Metzler; A C Arlt; W L Gross; J Brandt
Journal:  Ann Rheum Dis       Date:  2005-12       Impact factor: 19.103

Review 4.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

Authors:  Sherry Wolf; Debra Barton; Lisa Kottschade; Axel Grothey; Charles Loprinzi
Journal:  Eur J Cancer       Date:  2008-06-18       Impact factor: 9.162

Review 5.  Medication and toxin-induced peripheral neuropathy.

Authors:  Robert W Pratt; Louis H Weimer
Journal:  Semin Neurol       Date:  2005-06       Impact factor: 3.420

6.  Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.

Authors:  C Richez; P Blanco; A Lagueny; T Schaeverbeke; J Dehais
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

7.  Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy.

Authors:  Russell L Chin; William H Sherman; Howard W Sander; Arthur P Hays; Norman Latov
Journal:  J Neurol Sci       Date:  2003-06-15       Impact factor: 3.181

8.  Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

Authors:  Jean El-Cheikh; Anne-Marie Stoppa; Réda Bouabdallah; Hugues de Lavallade; Diane Coso; Jean-Marc Schiano de Collela; Thérèse Auran-Schleinitz; Jean-Albert Gastaut; Didier Blaise; Mohamad Mohty
Journal:  Clin Lymphoma Myeloma       Date:  2008-06

9.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Authors:  Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda T Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

10.  Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

Authors:  Neelima Denduluri; Jennifer A Low; James J Lee; Arlene W Berman; Janice M Walshe; Ujala Vatas; Catherine K Chow; Seth M Steinberg; Sherry X Yang; Sandra M Swain
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

View more
  6 in total

1.  Antibiotic-induced neurotoxicity.

Authors:  Shamik Bhattacharyya; Ryan Darby; Aaron L Berkowitz
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 2.  Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.

Authors:  Galen Leung; Marianna Papademetriou; Shannon Chang; Francis Arena; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 3.  Animal models of peripheral neuropathy due to environmental toxicants.

Authors:  Deepa B Rao; Bernard S Jortner; Robert C Sills
Journal:  ILAR J       Date:  2014

4.  Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate.

Authors:  E Babu; S Ramachandran; V CoothanKandaswamy; S Elangovan; P D Prasad; V Ganapathy; M Thangaraju
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

5.  Statins combined with niacin reduce the risk of peripheral neuropathy.

Authors:  Steven Lehrer; Peter H Rheinstein
Journal:  Int J Funct Nutr       Date:  2020-06-09

6.  Selective inhibition of soluble tumor necrosis factor signaling reduces abdominal aortic aneurysm progression.

Authors:  Silke Griepke; Emilie Grupe; Jes Sanddal Lindholt; Elizabeth Hvitfeldt Fuglsang; Lasse Bach Steffensen; Hans Christian Beck; Mia Dupont Larsen; Sissel Karoline Bang-Møller; Martin Overgaard; Lars Melholt Rasmussen; Kate Lykke Lambertsen; Jane Stubbe
Journal:  Front Cardiovasc Med       Date:  2022-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.